PFS CTC < 5 9.57 0.0549 CTC 5 4.87 ≥ CTC < 10 7.23 0.0942 CTC 10 4.87 ≥ CTC < 50 7.30 0.0251 CTC 50 4.67 ≥ Cycle 2 CTC < 5 6.93 <.0001 CTC 5 3.00 ≥ CTC < 10 6.93 <.0001 CTC 10 3.17 ≥ CTC < 50 6.90 <.0001 CTC 50 2.60 ≥ Supplemental Table 2: Changes in Gamma H2AX staining during chemotherapy Gamma 2 HX data % of CTCs expressing gH2AX Patient (Pts) with sig. increase baseline D1 D2 Pt 1 2 6 10 * Pt 2 20 18 20 Pt 2-C2 0 20 29 * Pt 7 2 3 7 Pt 8 0 0 54 * Pt 11 23 44 * Pt 13 3 10 * Pt 14 3 2 2 Pt 14 C2 1 2 3 Pt 19 22 43 * Pt 24 6 1 2 Pt 25 1 1 1 Pt 27 2 1 2 Pt 31 1 1 1 Pt 32 0 0 0 Pt 35 7 50 20 * Pt 36 9 25 8 *
PFS CTC < 5 9.57 0.0549 CTC ≥ 5 4.87 CTC < 10 7.23 0.0942 CTC ≥ 10 4.87 CTC < 50 7.30 0.0251 CTC ≥ 50 4.67 Cycle 2 CTC < 5 6.93 <.0001 CTC ≥ 5 3.00 CTC < 10 6.93 <.0001 CTC ≥ 10 3.17 CTC < 50 6.90 <.0001 CTC ≥ 50 2.60 Supplemental Table 2: Changes in Gamma H2AX staining during chemotherapy Gamma 2 HX data % of CTCs expressing gH2AX Patient (Pts) with sig. increase baseline D1 D2 Pt 1 2 6 10 * Pt 2 20 18 20 Pt 2-C2 0 20 29 * Pt 7 2 3 7 Pt 8 0 0 54 * Pt 11 23 44 * Pt 13 3 10 * Pt 14 3 2 2 Pt 14 C2 1 2 3 Pt 19 22 43 * Pt 24 6 1 2 Pt 25 1 1 1 Pt 27 2 1 2 Pt 31 1 1 1 Pt 32 0 0 0 Pt 35 7 50 20 * Pt 36 9 25 8 *
1-s2.0-S0169500217304476-mmc2.docx